Differences of survival benefits brought by various treatments in ovarian cancer patients with different tumor stages

He, Tingshan; Li, Hong; Zhang, Zhiqiao

doi:10.1186/s13048-023-01173-7

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2020, almost 314,000 new cases and 207,000 deaths have been reported [1,2]. Although the survival rates have improved during the past four decades, 70% of OC patients still succumb to the disease within ten years after diagnosis [3,4]. Current treatments are debulking surgery, followed by platinum-based chemotherapy; however, the overall clinical outcomes for OC patients continue to be unsatisfactory.…”

Section: Introductionmentioning

confidence: 99%

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

Szymanowski,

Szymanowska,

Bielawska

et al. 2023

Cancers

View full text Add to dashboard Cite

Ovarian cancer (OC) is the most common lethal gynecologic cause of death in women worldwide, with a high mortality rate and increasing incidence. Despite advancements in the treatment, most OC patients still die from their disease due to late-stage diagnosis, the lack of effective diagnostic methods, and relapses. Aptamers, synthetic, short single-stranded oligonucleotides, have emerged as promising anticancer therapeutics. Their ability to selectively bind to target molecules, including cancer-related proteins and receptors, has revolutionized drug discovery and biomarker identification. Aptamers offer unique insights into the molecular pathways involved in cancer development and progression. Moreover, they show immense potential as drug delivery systems, enabling targeted delivery of therapeutic agents to cancer cells while minimizing off-target effects and reducing systemic toxicity. In the context of OC, the integration of aptamers with non-coding RNAs (ncRNAs) presents an opportunity for precise and efficient gene targeting. Additionally, the conjugation of aptamers with nanoparticles allows for accurate and targeted delivery of ncRNAs to specific cells, tissues, or organs. In this review, we will summarize the potential use and challenges associated with the use of aptamers alone or aptamer–ncRNA conjugates, nanoparticles, and multivalent aptamer-based therapeutics for the treatment of OC.

show abstract

Section: Introductionmentioning

confidence: 99%